# REGAIN (Alpha DaRT in recurrent glioblastoma)

Source: https://onco.cc/trials/regain-alpha-dart/  
OnCo record `regain-alpha-dart` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A small early study of tiny radioactive sources placed inside glioblastoma that has come back. By November 2026 eight people had been treated and all were alive; the tumour had shrunk or disappeared on scans in the six assessed so far. There is no comparison group, follow-up is short, and half of the responses still need a confirming scan.

## Summary

REGAIN is a prospective, open-label, single-arm device study of intratumoural diffusing alpha-emitter radiotherapy (Alpha DaRT, titanium sources loaded with radium-224) for recurrent glioblastoma, registered as NCT06910306 by Alpha Tau Medical with 20 participants planned and three US sites listed. The registry gives no phase (a device feasibility study). Its primary endpoints are feasibility (successful placement of the sources) and safety (unanticipated grade 3 or higher adverse events); radiographic response by RANO criteria and overall survival to 12 months are secondary.

The Society for Neuro-Oncology 2026 abstract (Palmer and colleagues, Neuro-Oncology supplement) reports the safety analysis the FDA required after three patients, with data to May 2026: all planned sources deployed in all three, no unanticipated serious adverse event within 90 days, one grade 3 serious adverse event (a seizure with Todd's paralysis within 10 days of the implant, a 48-hour hospital stay, resolved with steroids), two complete responses on the 3-month MRI and one patient with a 30% decrease counted as stable disease.

The sponsor's release of 15 November 2026 updates this to a data cutoff of 11 November 2026, from the poster shown at the meeting: eight patients treated, all at Ohio State, with planned sources deployed in all eight and no unanticipated serious adverse event. Six had reached MRI assessment and all six had a RANO objective response as their best response: five complete responses (three confirmed, two awaiting confirmation) and one partial response (a 58% decrease, awaiting confirmation). The other two treated patients had not yet been assessed. All eight were alive; median follow-up from enrolment in the six assessed patients was 6.9 months (range 3.1 to 11.6) and median overall survival had not been reached.

Follow-up scans showed necrosis or suspected necrosis in or around the treated area in four of the six, all without symptoms. In two of those four, new or increased enhancement next to or outside the treated area could not yet be called necrosis or progression, and the sponsor says its recurrence figures may change. One patient progressed away from the treated area about nine months after treatment.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-18
- Also known as: REGAIN; CTP-GBM-01; Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy
- Tags: interim; single-arm; sponsor-reported; device
- Registry id: NCT06910306
- Phase: not-applicable
- Setting: Recurrent glioblastoma, one enhancing recurrence of 3 cm or less that is not suitable for surgery, after earlier brain radiotherapy: radium-224 Alpha DaRT sources placed inside the tumour, single arm
- Sponsor: Alpha Tau Medical
- Enrolled: 20
- Result: Interim and sponsor-reported (cutoff 11 November 2026): sources placed as planned in 8 of 8 treated patients; 6 of 6 assessed had a RANO response as best response (5 complete, 3 of them confirmed; 1 partial, unconfirmed); all 8 alive. Single arm, no comparator.
- Outcomes: Feasibility: planned sources deployed: Alpha DaRT 100 % of treated patients; Safety: unanticipated serious adverse events: Alpha DaRT 0 patients; Best radiographic response by RANO (complete or partial): Alpha DaRT 100 % of assessed patients; Alive at data cutoff: Alpha DaRT 100 % of treated patients
- Replication: None. This is an interim look at eight patients from one centre in a single-arm study with no comparison group, reported by the sponsor. It cannot show that responses last or that survival is longer than with other treatment; three of the six responses and the imaging findings in two patients were unresolved at the cutoff.

## Notes

- The registry record carries no acronym; REGAIN is the sponsor's name for the study, used in the Society for Neuro-Oncology abstract title.
- The sponsor's slides describe the safety endpoint as serious adverse events within 90 days and eligibility as up to three recurrences of IDH-wildtype grade 4 glioma; the registry words these differently. The registry text is the registered protocol.
- The sponsor describes necrosis as a known effect of focal radiation in brain that has been irradiated before, and says the investigators could not yet tell necrosis from progression in two patients; more imaging and, where needed, biopsy were planned.

## Sources

- ClinicalTrials.gov NCT06910306: https://clinicaltrials.gov/study/NCT06910306
- Palmer et al., REGAIN safety interim analysis, abstract CTNI-43 (Neuro-Oncology 2026;28 Suppl 4): https://doi.org/10.1093/neuonc/noag189.402
- Alpha Tau release of 15 November 2026, as filed with the SEC: https://www.sec.gov/Archives/edgar/data/1871321/000121390026120072/ea031236301ex99-1.htm
- Alpha Tau presentation of 16 November 2026, as filed with the SEC: https://www.sec.gov/Archives/edgar/data/1871321/000121390026120250/ea031237801ex99-1.htm

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- technologies: [Diffusing alpha-emitter radiation therapy (Alpha DaRT)](https://onco.cc/technologies/diffusing-alpha-emitter-radiotherapy/)
- companies: [Alpha Tau Medical](https://onco.cc/companies/alpha-tau-medical/)
- institutions: [The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute](https://onco.cc/institutions/osu-james/)

---
JSON: https://onco.cc/api/v1/entities/regain-alpha-dart.json